children with autism. If all goes as planned, NeuroPoint’s test will become available later this year, the company said.
“A manuscript [detailing key findings of the CAMP study] is in progress and will be submitted to a peer-reviewed scientific journal by the end of January,” Stemina co-founder and NeuroPoint CEO Beth Donley said in a prepared statement.
NeuroPoint’s $50,000 goal for its new crowdfunding campaign is a relatively modest amount, at least when compared to the cost of funding the CAMP study up to this point. The study has been supported by a $2.7 million grant from the National Institute of Mental Health, as well as a $3.8 million investment from the Nancy Lurie Marks Family Foundation, the company said.
